RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that Dr. Maria Maccecchini, CEO, will present an overview of neurodegenerative disorders, such as Alzheimer’s disease and discuss how QR Pharma’s new technology and approach promises to prevent the onset as well as the progression of the disease. The company’s lead compound, Posiphen®, inhibits a major pathway that leads to Alzheimer’s disease. The same pathway is also activated in head trauma, stroke and other brain insults and results in nerve cell death, cognitive impairment and dementia. QR Pharma’s lead compound is presently in a clinical study in Alzheimer’s patients and data will be available shortly.
